Our Science

The complement cascade plays a pivotal role in both innate and adaptive immune systems. It is responsible for recognizing and eliminating pathogens and damaged cells. 
Complement proteins are produced primarily by the liver and circulate in the blood and through the body’s tissues. The complement cascade may be activated through three principal pathways, known as the classical, lectin, and alternative pathways, all of which converge at C3. The C3 protein enables three principal immune responses: opsonization, inflammation and formation of the membrane attack complex. When C3 is activated, C3 fragments, such as C3b, tag cell surfaces in a process called opsonization, which marks the cells for removal from tissues or the bloodstream. Two other fragments, C3a and C5a, are released, contributing to inflammation in the surrounding tissues. Further complement activation causes membrane attack complex formation on cell surfaces, piercing holes and causing cells to lyse, or rupture. 
Under conditions of excessive or uncontrolled activation, the complement cascade is believed to play a key role in the onset and progression of a broad range of serious diseases. In these diseases, the complement cascade acts directly through tissue destruction by the membrane attack complex and indirectly by signalling other elements of the immune system to inappropriately target otherwise healthy tissues. Because the contribution of complement activation to the development and progression of these diseases is not fully understood, it has been difficult to develop therapeutics that ameliorate the conditions contributing to these diseases by targeting only one of the complement activation pathways. 

Diagram that illustrates the 3 pathways of complement activation, the essential role of C3 complement, and the effect of APL-2 (pegcetacoplan) on C3 activation

We have designed a C3 complement inhibitor to target complement proteins centrally at the level of C3. We believe that this approach can regulate uncontrolled or excessive complement activation that occurs in several debilitating diseases, including those within haematology, ophthalmology, neurology and nephrology. We believe that in some therapeutic areas, a C3 complement inhibitor may provide an alternative treatment option with the potential to address remaining unmet needs and in others it may provide a treatment option where today there is none. 


We use cookies to manage user experiences. Read our Cookie Statement for more information, including the purposes or vendors that we use.
User experience